Background: Erenumab is a monoclonal antibody blocking the calcitonin gene-related peptide receptor, which has been approved for the preventive treatment of chronic migraine (CM). The aim of this study was to explore the safety and effectiveness of erenumab in patients suffering from CM and medication overuse headache (MOH) in a real-life setting, up to 1 year.
Methods: Data regarding 81 patients treated with erenumab were retrospectively analyzed. Every 3 months, the following variables were collected: the mean number of headache days per month (headache index (HI)), the average number of painkillers taken per month (analgesic consumption (AC)), the mean number of days with painkiller consumption (number of days on medication (NDM)), the headache intensity (numeric rating scale (NRS) score), the 6-item Headache Impact Test (HIT-6), and the Self-Reported Instrument to Assess Work-Related Difficulties in Patients With Migraine (HEADWORK) scores.
Results: The HI, AC, and NDM and the NRS, HIT-6, and HEADWORK scores were significantly lower at every time point from the 3rd month onward compared to baseline (all P < 0.0001). No significant differences were found between patients who underwent painkiller detoxification before starting erenumab and those who did not (all P > 0.05). No significant differences were found between patients taking erenumab in combination with other preventive treatments and the ones taking it alone (all P ≥ 0.05). Five patients dropped out because of adverse events, which resolved after stopping erenumab.
Conclusion: Erenumab was safe and effective for CM complicated with MOH. Painkiller withdrawal and the association with other preventive treatment(s) seem useless.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10072-021-05105-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
T-2 Toxin Nephrotoxicity: Toxic Effects, Mechanisms, Mitigations, and Future Perspectives.
J Agric Food Chem
January 2025
College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China.
T-2 toxin is a highly toxic fungal toxin that threatens humans and animals' health. As a major detoxifying and metabolic organ, the kidney is also a target of T-2 toxin. This article reviews T-2 toxin nephrotoxicity research progress, covering renal structure and function damage, nephrotoxicity mechanisms, and detoxification methods to future research directions.
View Article and Find Full Text PDFDiagnosis of chronic obstructive pulmonary disease (COPD) in older patients : Consensus statement of the Working Group on Pneumology in Older Patients.
Z Gerontol Geriatr
January 2025
Geriatrie, Universität Witten-Herdecke, Alfred Herrhausenstraße 50, 58455, Witten, Germany.
Chronic obstructive pulmonary disease (COPD) is a frequent disease from which approximately 8% of individuals aged 40 years and above suffer. The prevalence increases up to fivefold as age advances. Following an introduction including the etiology, measurement, characteristic features and classification of COPD, this article presents the consensus recommendations of the German Working Group on Pneumology in Older Patients.
View Article and Find Full Text PDFMulti-class Classification of Retinal Eye Diseases from Ophthalmoscopy Images Using Transfer Learning-Based Vision Transformers.
J Imaging Inform Med
January 2025
College of Engineering, Department of Computer Engineering, Koç University, Rumelifeneri Yolu, 34450, Sarıyer, Istanbul, Turkey.
This study explores a transfer learning approach with vision transformers (ViTs) and convolutional neural networks (CNNs) for classifying retinal diseases, specifically diabetic retinopathy, glaucoma, and cataracts, from ophthalmoscopy images. Using a balanced subset of 4217 images and ophthalmology-specific pretrained ViT backbones, this method demonstrates significant improvements in classification accuracy, offering potential for broader applications in medical imaging. Glaucoma, diabetic retinopathy, and cataracts are common eye diseases that can cause vision loss if not treated.
View Article and Find Full Text PDFEfficacy and safety of teriparatide in kidney transplant recipients with osteoporosis and low bone turnover: a real-world experience.
Int Urol Nephrol
January 2025
Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Introduction: Kidney transplantation is the preferred treatment for end-stage kidney disease (ESKD), enhancing survival and quality of life. However, kidney transplant recipients (KTRs) are at high risk for bone disorders, particularly low bone turnover disease, which increases fracture risk. Teriparatide, an anabolic agent, may provide a beneficial treatment option for these patients.
View Article and Find Full Text PDFAge-threshold for increased risk of developing back disorders: prospective cohort with 74 000 individuals from the UK Biobank.
Eur Spine J
January 2025
Exercise Intervention for Health Research Group (EXINH-RG), Department of Physiotherapy, University of Valencia, Valencia, Spain.
Objective: To investigate the prospective associations between age and the risk of low back disorders (LBD), dorsal disorders (DD), and cervical disorders (CD), and to identify a potential age-threshold for increased risk of back disorders.
Methods: Prospective cohort from the UK Biobank comprising adults with no history of back disorders. We examined different ages and their association with the risk of back disorders derived from diagnoses of hospital registers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!